Rick Simpson Oil (RSO) in Kentucky: The Complete Guide by OilWell Cannabis

If you’re in Kentucky searching for Rick Simpson Oil, you’re not alone. From Louisville to Lexington, from the rolling hills of the Bluegrass to the coalfields of Eastern Kentucky, people are looking for real answers about this legendary cannabis extract. Maybe you’re a cancer patient whose doctor said it’s time to get affairs in order. Maybe you’re a veteran in Paducah struggling with PTSD after watching the pills do more harm than good. Maybe you’re a farmer’s wife in Owensboro living with chronic pain that makes every sunrise feel like a battle.

We understand. And we’re here to give you the complete, honest truth about RSO—what Rick Simpson actually made, what the science really says, and how our modern formulations offer something better: a legal, lab-tested, multi-cannabinoid RSO that respects both Simpson’s original mission and the evidence standards Kentucky deserves.

Understanding Rick Simpson Oil: The History Kentucky Needs to Know

Who Was Rick Simpson?

Rick Simpson wasn’t a doctor. He wasn’t a scientist. He was a power engineer from Nova Scotia—a blue-collar tradesman who understood machinery, not medicine. That matters for Kentucky readers because it makes his story relatable: he was an ordinary person who got failed by the medical establishment and decided to figure things out himself.

Born in 1949, Simpson’s life changed in 1997 when he fell from scaffolding at a hospital in Moncton. The irony wasn’t lost on him—injured at a hospital, then failed by the medical system that followed. He developed persistent tinnitus, dizziness, and post-concussion symptoms that prescription drugs couldn’t touch, or made worse. When he discovered cannabis helped and asked his doctor to consider it, the door slammed shut. That rejection—that experience of being told “no” by the very system supposed to help—resonates across Kentucky, where we’ve seen our own healthcare gaps and where many folks have learned to keep quiet about the remedies that actually work for them.

Simpson’s pivotal moment came in 2003, when he claimed three bumps on his arm—diagnosed as basal cell carcinoma—disappeared after applying cannabis oil. No biopsy. No independent verification. No clinical documentation. We say this not to dismiss his story, but to honor it honestly. That personal testimony became the origin myth of RSO, and it sparked a global movement. But Kentucky readers deserve to know the difference between a powerful personal story and medical evidence.

The Crusade: How RSO Became a Global Phenomenon

After his 2003 experience, Simpson went all-in. He started producing concentrated cannabis oil in Maccan, Nova Scotia, and gave it away for free to cancer patients and anyone else who asked. He helped people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia—the list grew with every testimonial. He charged nothing. That free-distribution model is core to his legacy; it’s something we at OilWell carry forward in our open-source philosophy (more on that later).

His story exploded through the 2005 documentary Run From The Cure, which spread online and became foundational cannabis education for millions. If you’re in Kentucky and first heard about RSO through an online forum, a Facebook group for cancer patients, or a veteran’s support network, you can trace that information lineage back to Simpson’s film.

But the crusade brought legal consequences. The Royal Canadian Mounted Police raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Eventually, the legal pressure forced him to leave Canada for Europe, where he continued his advocacy from Croatia and the Netherlands. This history matters for Kentucky because it contextualizes the legal risk that defined early cannabis work—risk that still echoes in states like ours where cannabis remains heavily restricted.

The Traditional RSO Protocol: What Simpson Actually Recommended

Simpson’s famous 60-gram, 90-day protocol wasn’t invented in a lab. It was born from his personal experience and the feedback loop of testimonials he collected. Here’s exactly what he prescribed:

Goal: Consume 60 grams of concentrated cannabis oil over roughly 90 days. Simpson considered this the minimum for serious cancer treatment.

Week 1: Start with a dose half the size of a grain of rice—about 10-15 mg of oil—three times daily. Total daily intake: 30-45 mg. The goal was gradual introduction to THC’s psychoactive effects.

Weeks 2-5: Double the dose every four days. By week five, reach approximately 1 gram (1,000 mg) of oil per day, divided into three doses of about 333 mg each.

Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed. At this dosing level, you’re taking roughly 600-900 mg of THC daily (assuming 60-90% THC content in traditional RSO).

Administration:

• Oral/sublingual: Primary method for systemic absorption
• Topical: For skin cancers, applying directly to lesions with bandages
• Inhalation: Simpson didn’t recommend it as primary treatment, only for immediate symptom relief

Important context for evaluating this protocol:

• No controlled trial validation. Not one published randomized controlled trial, cohort study, or even well-documented case series supports this specific protocol for any cancer type.
• Crude, unstandardized material. Every batch of traditional RSO varied wildly in potency depending on the strain, growing conditions, and extraction technique. The 60-gram quantity assumes a potency that was never guaranteed.
• Extremely high THC exposure. At peak dosing, 600-900 mg of THC daily is 30-45 times the typical dose of FDA-approved dronabinol (2.5-20 mg/day). This carries serious risks: severe intoxication, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [15].
• Real risks for medically complex patients. Kentucky cancer patients often have multiple health issues. Using unregulated, unstandardized oil as a primary treatment—potentially in place of proven therapies—introduces harm beyond the oil itself.

We present this protocol fully because Kentucky readers searching for “RSO dosing” need to find complete information, not sanitized marketing. But we also present it honestly because that’s what you deserve.

What Traditional RSO Actually Was as a Product

Source material: Single high-THC indica strains with no standardization. Simpson favored heavy indicas and recommended against sativas, but there was no batch-to-batch consistency.

Extraction solvent: Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other toxic compounds. This is one of the biggest safety improvements modern formulations have made.

Extraction process: A bucket, solvent, agitation, filtering through cheesecloth, then evaporating the solvent in a rice cooker. The heat was high enough to decarboxylate all THCa into THC and destroy most terpenes.

Appearance: Nearly black, thick, tar-like oil with a strong cannabis and possible solvent-residual smell.

Cannabinoid profile: Fully decarboxylated, THC-dominant (60-90% estimated), with minor cannabinoids at whatever ratios the source strain provided. No control, no measurement, no lab verification.

Terpene content: Essentially zero. The solvent and heat volatilized these compounds away.

Standardization and testing: None whatsoever. No Certificates of Analysis, no potency verification, no contaminant screening.

Residual solvent risk: Potentially significant. Incomplete purging leaves toxic residues that are difficult to verify without lab testing.

Simpson’s Claims vs. The Evidence Record

Let’s be direct, Kentucky: Simpson claimed RSO could cure cancer and many other diseases. He was adamant and consistent. But what does the actual evidence show?

What Simpson was not: He wasn’t a scientist, physician, pharmacologist, or researcher. He never conducted or published a clinical trial. His evidence was personal testimony and informal testimonials—no controls, no verification, no follow-up.

What the preclinical literature shows: Laboratory and animal studies demonstrate that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal models show some tumor-growth inhibition. This is scientifically interesting and warrants further research .

What the preclinical literature does NOT show: These findings have not translated into proven human cancer cures. The gap between lab results and human outcomes is vast across all oncology research. No human clinical trial has demonstrated that RSO or any cannabis oil cures cancer .

Institutional positions:

• National Cancer Institute: Acknowledges anticancer research in labs and animals but does not endorse cannabis as cancer treatment .
• FDA: Has not approved any cannabis plant product for cancer. Only Epidiolex (CBD for seizures) and synthetic THC analogues for chemo nausea and AIDS wasting have FDA approval [1].
• Health Canada: Never approved RSO or cannabis oil as cancer cure.
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite—not cancer [1].

What Simpson got right: He drew attention to cannabinoids as serious biomedical research when the world ignored them. His advocacy helped create the conditions for today’s legal cannabis industry and research infrastructure. He brought concentrated cannabis oil to global awareness. Those contributions are real and significant.

What he overstated: The leap from preclinical signals to cancer cure was never supported by human evidence. Encouraging cancer patients to rely on RSO instead of proven therapies (surgery, radiation, chemo, immunotherapy) carries genuine harm potential. Delayed treatment for treatable cancers is a documented concern in alternative medicine.

Kentucky, we tell you this not to dismiss Simpson’s legacy, but to honor it honestly. He started a conversation that needed to happen. We’re continuing that conversation with the evidence standards that modern patients deserve.

The Evolution from Traditional RSO to Modern Formulations

The term “RSO” has become generic. Walk into a dispensary in Louisville (if Kentucky had them) and “RSO” on a label could mean almost any full-spectrum extract—regardless of extraction method, cannabinoid profile, or quality. Simpson himself has criticized commercial products that depart from his original method and philosophy.

Simpson’s model was anti-commercial. He gave oil away free and taught people to make their own. The modern industry commercialized what he distributed freely. Whether that’s improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, gatekeeping) depends on your perspective.

What isn’t disputed is that modern RSO has evolved substantially—and those changes matter for Kentucky patients.

The OilWell Story: From a Dog Named Bentley to Kentucky Patients

Our Origin: When Love Meets Science

OilWell Cannabis was founded in Houston, Texas by Colin Valencia, who grew up in McAllen—right across the river from Reynosa, Mexico. The Borderplex is one of America’s most economically challenged and dangerous regions, marked by poverty, cartel violence, and limited opportunities. Colin’s childhood involved transporting items across the border, watching friends killed or imprisoned, and leaving home at sixteen after facing every form of violence imaginable.

Despite that environment, Colin chose cannabis over darker paths. He grew up in the traditional cannabis world pre-legalization, learning the plant intimately while operating in the shadows. He later became a formally trained software engineer who did custom development work for Baylor College of Medicine—one of America’s most prestigious medical institutions. That combination of deep cannabis knowledge and medical-grade technical precision defines every product we make.

But OilWell didn’t start with a business plan. It started with a dog named Bentley.

Bentley was more than a pet—he was family. When Bentley became paralyzed in his back legs and faced euthanasia, veterinarians said pain medications would destroy his organs. The choice was prolonged suffering or immediate mercy killing. Giving up wasn’t an option.

A rescue worker named Jessica asked Colin a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That exposed a blind spot in Colin’s cannabis knowledge—it was all recreational, never therapeutic.

Determined to save Bentley, Colin created a CBD golden paste. It wasn’t a cure, but it was hope. And that hope delivered the impossible: Bentley got up, walked over, and brought his ball to play. From paralyzed to playing fetch. This wasn’t placebo—dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition: neurodegeneration led him to CBG’s neuroprotective properties and THCa’s PPARγ agonism; dementia led to CBC’s neurogenesis role; glaucoma led to THC’s CB1 agonism; arthritis led to multi-pathway anti-inflammation using CBD, CBG, THCa, and beta-caryophyllene.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Precision mattered—his life depended on formula accuracy, not guesswork.

Colin’s Personal Journey: From Benzo Addiction to Formulation Mastery

Colin knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to quit Xanax, he went cold turkey—a notoriously dangerous feat—using the cannabinoid knowledge he’d developed saving Bentley.

Our Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This isn’t theoretical knowledge. He lived what Kentucky patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

Over time, the therapeutic benefits Colin discovered through Bentley became the core of our work. We’ve developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been making cannabis accessible and effective for everyone—vegans, diabetics, those with specific health needs.

Media Recognition: Mainstream Validation from Houston to Kentucky

Between 2019 and 2023, ABC13 Houston—America’s fourth-largest city’s top news source—featured Colin and OilWell in seven comprehensive news segments. Five different reporters sought our expertise across business, law, medicine, community health, and politics. No other Houston cannabis operator matches that frequency or breadth.

September 2019: Our first feature introduced our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.” That quote is our foundation.

March 2021: We were featured as ecosystem builders helping other entrepreneurs enter legal cannabis—the therapy quote: “Pain comes in a lot of different forms.”

May 2021: In a Delta-8 investigation, Steve Campion asked why someone would want to get high. Colin’s honest answer—“Maybe you want to get high”—became iconic for its radical transparency.

August 2021: We gave away $35,000 worth of product (1,000 caviar pre-rolls) to encourage COVID vaccination, coordinating with the city of Houston. No political agenda—just community health.

October 2021: When Texas banned Delta-8 overnight, we proactively removed all products and warned other operators they were unknowingly shipping Schedule I narcotics. We absorbed the revenue loss to act ethically.

October 2022: We revealed Colin’s personal marijuana conviction history in the context of Biden’s pardon announcement. That transforms our entire story—we’re not outsiders; we’ve lived the consequences.

April 2023: On 4/20, we framed the present as a “Renaissance” moment for Texas cannabis, with industry context that applies to Kentucky’s emerging market.

This media record—earned, not purchased—establishes credibility that transcends geography. When Kentucky readers see our Houston address, know that we’ve been vetted by major-market journalism in ways most cannabis companies never achieve.

The OilWell RSO Philosophy: Four Principles for Kentucky

Our RSO is not traditional RSO. It’s informed by that tradition but deliberately different in ways that solve problems Simpson couldn’t address. Four core principles define our approach:

1. Accessibility Over Gatekeeping

For Kentucky, this means: No medical card required. If you’re 21 or older in Louisville, Lexington, Bowling Green, or anywhere else in Kentucky, you can legally purchase our products. We ship nationwide, including to every Kentucky county—from Jefferson to Pike, from Fayette to McCracken.

Simpson believed medicine should be accessible to everyone. We built a product and distribution model that makes that accessible legally. While Kentucky’s medical cannabis program remains extremely limited (only CBD oil with <0.3% THC for a handful of conditions), our Farm Bill-compliant products bypass those restrictions entirely.

2. Patient-Controlled Potency

For Kentucky, this means: You decide if your medicine is psychoactive or not. Our sublingual oil contains 1,500mg of THCa—the acidic, non-psychoactive precursor to THC. Use it raw, and you get anti-inflammatory benefits with zero impairment. Heat it at home (260°F for 45-60 minutes), and it converts to approximately 1,315mg of delta-9 THC, giving you full psychoactive potency comparable to traditional illegal RSO.

This is revolutionary for Kentucky’s working people. A coal miner in Harlan County can use the raw form during his shift without impairment. A teacher in Lexington can manage daytime pain while staying clear-headed. A veteran in Fort Campbell can decarboxylate for nighttime PTSD relief. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry, not rhetoric.

3. Open-Source Formulas

For Kentucky, this means: We publish our complete formulas publicly. If our $129.99 sublingual oil is beyond your budget, you can see exactly what’s in it and make your own version. We sell a professionally manufactured, lab-tested product for those who want convenience, and we give away the recipe for those who need to DIY.

This echoes Simpson’s free-distribution ethos. He gave oil away and taught people to make it. We adapted that for the modern marketplace: professional quality with transparency.

The Bentley golden paste recipe we published years ago is still free for any Kentucky pet owner facing a similar crisis:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil
• 1-2 teaspoons black pepper
• CBD oil (veterinarian consultation recommended)

We didn’t start with RSO formulas—we started with Bentley. The pattern is consistent: give away what saves lives.

4. Evidence-Informed, Not Evidence-Overstating

For Kentucky, this means: We tell you exactly what the science says and doesn’t say. The GENERAL KNOWLEDGE section of this document is our commitment to honest education. When we claim CBD has strong evidence for seizures, we cite the research [1][2]. When we admit CBN’s sleep evidence is weak, we tell you that too [16][17].

Simpson operated without access to peer-reviewed literature. We have that access and use it to distinguish between what’s well-supported, what’s emerging, and what’s overstated. Kentucky readers deserve that honesty—especially when making decisions about cancer, chronic pain, or end-of-life care.

Farm Bill Compliance: How Kentucky Residents Can Access RSO Legally

The Legal Framework That Makes This Possible

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC at the federal level. Our RSO Sublingual Oil contains only 90mg of delta-9 THC in the entire 30mL bottle—3mg per mL—well under the 0.3% threshold. All cannabinoids are hemp-derived.

THCa: The Legal Distinction

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It’s not itself delta-9 THC, which is legally significant. Our product is Farm Bill compliant at the point of sale. Kentucky law prohibits recreational cannabis but does not restrict hemp-derived cannabinoids with <0.3% delta-9 THC.

Patient-Controlled Activation: Three Usage Options

Option 1: Raw (Non-Psychoactive)
Use the oil without heating. All 1,500mg of THCa stays in its acidic form. You get anti-inflammatory benefits via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12], with zero impairment. Perfect for daytime use in Louisville’s workplace, driving Kentucky’s country roads, or managing pain while parenting in Bowling Green.

Option 2: Fully Activated (Home Decarboxylation)
Heat the oil at 260°F for 45-60 minutes. This converts 1,500mg THCa → ~1,315mg delta-9 THC. Combined with the existing 90mg delta-9 THC, you get ~1,405mg total delta-9 THC. Add the 6,000mg delta-8 THC, and you achieve psychoactive potency comparable to traditional illegal RSO—100% legally, because activation happens in your Kentucky kitchen after purchase.

Option 3: Vape (Instant Decarboxylation)
Our 1-gram vape cartridge heats to 400-450°F, instantly converting THCa with each puff. Onset in 1-2 minutes for breakthrough pain, panic attacks, or acute nausea.

Conversion Chemistry: 1mg THCa = 0.877mg delta-9 THC after decarboxylation (accounting for CO₂ loss).

Legal Notice for Kentucky Customers

THCa converts to delta-9 THC when heated. You are responsible for understanding Kentucky law regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. Kentucky residents must verify local legality before decarboxylation.

Solvent-Free Production: Safety Kentucky Can Trust

Traditional RSO used naphtha or isopropyl alcohol—toxic, non-food-grade solvents that may leave harmful residues. We don’t extract that way. Our RSO is a formulated blend of individual cannabinoid distillates and isolates combined in a controlled environment.

No naphtha. No butane. No isopropyl alcohol. No extraction solvents in the finished product.

We use organic MCT oil as our carrier base—food-grade, facilitating sublingual absorption, with a neutral taste. No tar-like consistency. No solvent-residual odor.

Third-Party Lab Testing: Every batch is tested for:

• Cannabinoid potency (±2% accuracy)
• Heavy metals (arsenic, cadmium, lead, mercury)
• Pesticides (400+ compounds)
• Residual solvents (FDA Class 3 limits <5,000 ppm)
• Microbial contaminants

Certificates of Analysis are available on request and through our website. For Kentucky customers, this level of transparency is crucial—especially if you’ve seen contaminated products in less regulated markets.

Two Product Formats for Kentucky Lifestyles

RSO Sublingual Oil – $129.99

Specifications:

• 30mL bottle (1 fl oz)
• 16,590mg total cannabinoids (553mg/mL)
• Seven cannabinoids: CBD 4,500mg, CBG 3,000mg, delta-8 THC 6,000mg, THCa 1,500mg, delta-9 THC 90mg, CBN 750mg, CBC 750mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper (0.1mL increments)

Pharmacokinetics:

• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%

Doses per bottle: 40-60 depending on serving size

RSO Vape Cartridge – $49.99

Specifications:

• 1-gram cartridge
• 900mg+ total cannabinoids
• Six cannabinoids (THCa auto-decarbs at vaping temp)
• Live terpenes at 5%+
• 510-thread universal battery compatibility

Pharmacokinetics:

• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

When to Use Each Format in Kentucky

Kentucky Use Case	Recommended Format	Why
Acute breakthrough pain (mine work, farming injury)	Vape	1-2 minute onset for immediate relief
Chronic daily pain (arthritis, fibromyalgia)	Sublingual	4-6 hour sustained duration
Nighttime sleep support	Sublingual (2mL)	Delivers 50mg CBN for sleep architecture
Daytime functional relief (work, driving)	Sublingual raw	Zero psychoactive impairment
Chemo nausea (Louisville cancer centers)	Vape	Fast relief; sublingual pre-dose for sustained effect
Anxiety (PTSD, panic)	Vape + sublingual	Vape for acute attacks, sublingual for baseline
Cost-conscious Kentucky buyer	Sublingual	More doses per dollar; open-source recipe available

Competitive Comparison: Why OilWell for Kentucky

OilWell RSO vs. Kentucky’s Limited Medical Program (TCUP)

Feature	Kentucky TCUP	OilWell RSO
Access	Requires qualifying condition card	Age 21+, no medical card needed
Cannabinoids	THC-only (if available)	7 cannabinoids: CBD, CBG, delta-8, THCa, delta-9, CBN, CBC
CBG/CBN/CBC	Not available	3,000mg CBG, 750mg CBN, 750mg CBC
Patient-controlled potency	No	Yes—THCa raw or decarbed
Delivery	Must travel to dispensary (limited locations)	Ships directly to any Kentucky address
Psychoactive option	Limited	Yes—via decarboxylation

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Feature	Typical Hemp RSO	OilWell RSO
Total cannabinoids	~1,000mg	16,590mg
CBD content	~950mg	4,500mg
Delta-8 THC	0mg	6,000mg (pain, anti-nausea)
THCa (psychoactive potential)	Minimal	1,500mg (converts to ~1,315mg delta-9)
Price	$40-50	$129.99 (33x more cannabinoids per dollar)

OilWell RSO vs. Traditional Illegal RSO

Feature	Traditional RSO	OilWell RSO
Source	Single strain	Multi-cannabinoid blend
Cannabinoids	60-90% THC only	7 defined cannabinoids at precise ratios
Terpenes	Destroyed	Live terpenes at 5%
Testing	None	Full panel COA
Solvents	Naphtha/isopropanol	Solvent-free formulation
Standardization	None	553mg/mL consistent potency
Legal risk	Schedule I (illegal)	Farm Bill compliant
Access	Underground only	Ships legally to Kentucky

Condition-Specific Usage Context for Kentucky

Important disclaimer: The following contexts are informed by research cited throughout this document. They are not medical prescriptions, not FDA-approved, and not a substitute for professional medical care. These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before use, especially if you have medical conditions, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea & Appetite Support

For Kentucky cancer patients in Louisville’s Norton Cancer Institute or Lexington’s UK Markey Cancer Center:

• Pre-chemo: 0.5-1.0mL sublingual oil approximately 1 hour before treatment to establish baseline cannabinoid levels.
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset).
• Post-chemo: 0.5mL sublingual every 6 hours as needed.
• Sleep during treatment: 1.0-2.0mL sublingual before bed delivers 25-50mg CBN, supporting sleep architecture when pain and anxiety make rest elusive.

Evidence context: Delta-8 THC shows antiemetic properties [9]; delta-9 THC is established for chemo nausea [1][13]; CBD provides anxiolytic buffering [3].

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

For Kentucky’s high rates of chronic pain, especially in manual labor and aging populations:

• Daytime functional relief: 0.3-0.5mL raw sublingual oil. No psychoactivity, no impairment for work or driving through the Daniel Boone National Forest.
• Nighttime relief: 0.5-1.0mL decarboxylated sublingual. Combines pain relief with CBN’s sleep support.
• Breakthrough pain: Vape as needed for rapid onset during flare-ups.

Evidence context: CBD shows pain-modulating effects [4]; delta-9 THC demonstrates analgesic activity [13]; beta-caryophyllene activates CB2 receptors for anti-inflammatory action [24]; THCa inhibits COX-2 [12].

Sleep Support

For Kentuckians struggling with insomnia, especially veterans with PTSD:

• Before bed: 1.0-2.0mL sublingual oil.
• At 2.0mL: Delivers 50mg CBN—the dosage investigated in 2024 sleep literature [17].
• At 1.0mL: Delivers 25mg CBN, above the 20mg threshold associated with reduced sleep disturbance [16].

Evidence context: CBN sleep evidence is emerging but not yet robust [16][17]; cannabis overall shows modest sleep benefits in review literature [17].

Anxiety, Stress & PTSD

For Kentucky’s veteran communities, first responders, and trauma survivors:

• Daytime functional relief: 0.3mL raw sublingual. CBD and CBG address anxiety pathways without psychoactive impairment.
• Nighttime: 1.0mL sublingual. Full cannabinoid profile including CBN for sleep architecture support.

Evidence context: CBD demonstrates anxiolytic effects [3]; CBG shows pharmacologic promise [7][8]; limonene may contribute to mood elevation via entourage effects [20].

General Titration Principle for Kentucky Users

Start low, go slow. Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Kentucky’s varied metabolism, body weights, and medication regimens mean individual responses differ significantly.

Delivery to Kentucky: From Houston to Your Doorstep

Nationwide Shipping to Every Kentucky County

We ship to all 120 Kentucky counties, from urban Jefferson to rural Martin. All orders include:

• USPS Priority Mail (2-3 business days)
• FedEx/UPS Ground (3-5 business days)
• Discreet packaging (no cannabis branding visible)
• Tracking for all shipments
• Temperature-stable packaging for Kentucky summers
• Signature-required option available

International Shipping

We ship globally to jurisdictions where hemp-derived products with <0.3% delta-9 THC are legal. International Kentucky expatriates or those with family overseas can access the same formulas. All packages include full documentation, Certificates of Analysis, and customs receipts. Customer accepts all customs and legal responsibility.

Ordering Information

Website: OilWellCBD.com

Phone: (832) 416-2816

Email: [email protected]

Address: 810 Richmond Avenue, Houston, TX 77006 (Montrose neighborhood)

Business Hours:

• Monday-Thursday: 10:00 AM – 7:00 PM
• Friday-Saturday: 10:00 AM – 10:00 PM
• Sunday: 10:00 AM – 4:00 PM

The Science Behind Our Formula: Evidence for Kentucky Readers

Research Method: How We Evaluate Evidence

We prioritize sources in this order: human clinical evidence, systematic reviews, NIH institutional summaries, then preclinical literature. This matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human data; other compounds rely more on reviews and animal studies [1]-[29].

Institutional Baseline: What NIH Says

• Strongest evidence: Rare epilepsies (CBD), chemo nausea (THC), HIV/AIDS appetite (THC) [1].
• Modest evidence: Chronic pain, multiple sclerosis symptoms [1].
• Safety concerns: Impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, contamination, labeling inaccuracy, vape-related lung injury [1].

Cannabinoid Evidence Profiles

CBD (4,500mg in our formula)

• Strongest evidence: Seizure disorders (Epidiolex FDA-approved) [1][2].
• Anxiety: 2024 meta-analysis shows anxiolytic signal but limited clinical samples [3].
• Pain: 2024 review finds promising but heterogeneous results [4].
• Sleep: 2023 review shows weak methodology in existing studies [5].
• Safety: 2023 meta-analysis identifies liver enzyme elevation risk, especially with polypharmacy [6].

CBG (3,000mg)

• Evidence: Mostly preclinical; human data sparse [7][8].
• Pharmacology: Precursor to major cannabinoids; interacts with cannabinoid, alpha-2 adrenoceptor, and 5-HT1A systems [7].
• Research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity—all preclinical [7][8].
• Caution: Commercially sold despite thin evidence [7].

Delta-8 THC (6,000mg)

• Evidence: Pharmacologically relevant but less clinically characterized than delta-9 [9]-[11].
• Pharmacology: Partial CB1 agonist, less potent than delta-9 [9].
• Public health: 2023 scoping review shows adverse consequences, manufacturing concerns [10].
• Bottom line: Psychoactive analogue with real activity but incomplete safety data [9]-[11].

THCa (1,500mg)

• Evidence: Important chemically but low direct human therapeutic evidence [12].
• Psychoactivity: Non-psychoactive unless heated/decarboxylated [12].
• Research: In vitro/rodent studies suggest anti-inflammatory, neuroprotective, antineoplastic possibilities—not established human outcomes [12].

Delta-9 THC (90mg total)

• Evidence: Strongest psychoactive cannabinoid data, but clearest adverse effects [1][13]-[15].
• Institutional support: Chemo nausea, HIV/AIDS appetite, some pain/MS symptoms [1].
• Safety: High-concentration products linked to psychosis, schizophrenia, CUD [15]; anxiety, panic, tachycardia, hypotension at high doses [1][14].
• Bottom line: Therapeutic relevance but significant safety liabilities [13]-[15].

CBN (750mg)

• Evidence: Weak human evidence; marketing ahead of data [16][17].
• Sleep claims: 2021 review found no clinical trials using validated sleep measures [16].
• Bottom line: Reputation stronger than clinical evidence [16][17].

CBC (750mg)

• Evidence: Emerging, preclinical [18][19].
• Potential: Distinct pharmacodynamics; antinociceptive, antibacterial, anti-seizure interest [18].
• Caution: Over-the-counter products sold despite little efficacy/safety evidence [18].

Terpene Evidence Profiles

Important note: Terpene claims need stricter interpretation than cannabinoids. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust human proof of entourage effects remains limited [20][29].

Limonene (citrus-bright)

• Multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective potential—but mostly non-human literature [21].
• Oxidation products are contact allergens [22].

Myrcene

• Preclinical anxiolytic, anti-inflammatory, analgesic properties; human studies lacking [23].
• Common “sedation” claims exceed current evidence [20][23].

Caryophyllene (β-caryophyllene – pepper/spice)

• Selective CB2 receptor agonist—mechanistically interesting [24].
• Anti-inflammatory, immunomodulatory, neuroprotective potential—but human confirmation limited [24].

Pinene (forest-fresh)

• Preclinical antioxidant, anti-inflammatory, neuroprotective signals; clinical trials lacking [25].
• “Memory enhancement” claims remain exploratory [20][25].

Linalool (floral, lavender)

• Preclinical stress/mood/brain health potential; limited human trials [25][26].
• Oxidized hydroperoxides are allergens [22].

Humulene (earthy, woody)

• Preclinical anti-inflammatory; some rodent cannabimimetic properties via CB1/adenosine pathways [27].
• “Appetite suppressant” claims lack human confirmation [27].

Terpinolene (piney, fruity)

• Least clinically characterized; 2021 review found no human trials [20][28].
• Biologically interesting but underdeveloped [20].

Research Limits: What Kentucky Readers Should Know

1. Evidence is highly uneven. CBD and delta-9 THC support detailed statements; others require caution [1]-[29].
2. Extract types aren’t interchangeable. Whole-cannabis, purified-molecule, semisynthetic, and terpene-only data differ significantly.
3. Minor cannabinoids are commercially interesting because they’re underexplored—meaning claims often outrun science.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, and dose variability affect real-world outcomes [1][10][11][14].
5. THCa chemistry changes with storage/heating. The same product can become more psychoactive over time or with heat exposure [12].

Common Overstatements to Avoid (And What to Say Instead)

• Don’t say: “CBN is a proven sleep aid.”
  Say: “CBN is marketed for sleep, but human evidence remains weak and dated [16][17].”

• Don’t say: “Myrcene makes you sleepy.”
  Say: “Myrcene has preclinical anxiolytic and analgesic properties, but human sedation claims exceed current evidence [20][23].”

• Don’t say: “Terpenes have proven entourage effects.”
  Say: “Entourage hypotheses are influential but lack robust human clinical proof [20][29].”

• Don’t say: “THCa is always non-psychoactive.”
  Say: “THCa itself isn’t psychoactive, but heating converts it to THC, changing effects [12].”

• Don’t say: “Delta-8 THC is safe because it’s hemp-derived.”
  Say: “Delta-8 THC is psychoactive with incomplete safety characterization and manufacturing concerns [9]-[11].”

Our Formulas: Complete Transparency for Kentucky DIYers

RSO Sublingual Oil Formula (Open-Source)

Cannabinoid	Amount (mg)	% of Total
CBD	4,500	27.1%
CBG	3,000	18.1%
Delta-8 THC	6,000	36.2%
THCa	1,500	9.0%
Delta-9 THC	90	0.5%
CBN	750	4.5%
CBC	750	4.5%
Total	16,590	100%

• Live terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: Organic MCT oil
• Format: 30mL with graduated dropper

For Kentucky DIY makers: You can source these individual distillates and isolates from reputable suppliers (ensure COAs showing <0.3% delta-9 THC at purchase). Mix in these exact ratios in organic MCT oil. Heat gently to combine, but do not exceed 200°F if you want to preserve THCa. We publish this because Simpson taught people to make their own, and Kentucky patients deserve that same empowerment.

RSO Vape Cartridge Formula (Open-Source)

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%
Live terpenes	5%+

• Format: 1-gram 510-thread cartridge
• Battery: Universal compatibility (available at any Kentucky vape shop)

Note: THCa auto-decarboxylates at vaping temperature (400-450°F), so each puff delivers freshly activated cannabinoids.

Terpene Profile: Sensory Experience for Kentucky

Both products contain the same seven terpenes:

• Limonene (citrus-bright): Uplifting aroma reminiscent of Kentucky’s citrus groves (if we had them!)
• Myrcene: Earthy base note, common in hops (connecting to Kentucky’s brewing heritage)
• Caryophyllene (pepper/spice): Warm, spicy scent like a good Kentucky bourbon barrel
• Pinene (forest-fresh): Piney aroma evoking Kentucky’s woodlands
• Linalool (floral, lavender): Calming floral notes
• Humulene (earthy, woody): Deep, grounding aroma
• Terpinolene (piney, fruity, sparkling): Complex top notes

This profile complements the cannabinoid formula—limonene for mood elevation, myrcene for relaxation, caryophyllene for CB2 activation, pinene for mental clarity, linalool for calm, humulene for inflammation, terpinolene for sensory complexity.

Conclusion: A New Chapter for Kentucky

Kentucky, we know your story. We know the opioid crisis has hit your communities hard. We know cancer rates are high, especially in the tobacco-growing regions. We know veterans are struggling with PTSD and limited treatment options. We know your medical cannabis program is so restrictive it barely functions. We know you’ve been failed by systems that should help.

That’s why we’re here. Not to sell snake oil. Not to sell false hope. But to give you the best possible version of the information so you can give it a fair shot and decide if it’s right or wrong for you.

Our RSO is legal, lab-tested, multi-cannabinoid, and patient-controlled. It honors Rick Simpson’s mission of accessibility while meeting the evidence standards Kentucky deserves. It ships directly to your door in Winchester, in Ashland, in Hopkinsville, in every corner of the Commonwealth.

Ready to learn more?

Visit our complete RSO guide: OilWellCBD.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Or call us directly: (832) 416-2816

We’re not a faceless corporation. We’re a company built on a dog named Bentley, a man’s battle with benzo addiction, and seven years of media accountability. We’re ready to serve Kentucky with the same integrity we’ve shown Texas.

Because pain comes in a lot of different forms. And Kentucky deserves options that are honest, legal, and effective.